Eli Lilly One Team - Search News

Eli Lilly posts mixed quarter

The Associated Press - Busines… · 10h

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

BioPharma Dive · 6h

Eli Lilly’s earnings, shares lifted by obesity drug sales

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.

CNBC on MSN · 12h

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

FierceBiotech6h

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

12don MSN

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

14d

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results